Incretin Mimetics and Amylin Analogues

Nisha K. Patel, Pharm.D., Emily Pherson, Pharm.D., Brian Pinto, Pharm.D., Ana Emiliano, M.D.



  • Incretin mimetics also knownn as GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, semaglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
    • High-dose liraglutide (Saxenda™) and semaglutide (Wegovy™): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
  • Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: September 3, 2021